Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Ascites Market Outlook

Thelansis’s “Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ascites Overview

Ascites are the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often marking the transition from compensated to decompensated cirrhosis. Approximately 50% of patients with decompensated cirrhosis develop ascites within 10 years, leading to increased mortality due to complications like spontaneous bacterial peritonitis and hepatorenal syndrome. In the United States, cirrhosis is the leading cause of ascites, accounting for about 80% of cases. Other causes include cancer (10%), heart failure (3%), tuberculosis (2%), dialysis (1%), pancreatic disease (1%), and other factors (2%). Hemorrhagic ascites, occurring in up to 19% of cirrhosis patients, may result from spontaneous causes, with 72% attributed to bloody lymph and 13% to hepatocellular carcinoma. The initial abnormality in cirrhosis-related ascites is portal hypertension, where increased portal pressure and elevated circulating nitric oxide levels lead to vasodilation. As vasodilation progresses, plasma levels of vasoconstrictor sodium-retentive hormones rise, renal function declines, and ascitic fluid accumulates, indicating hepatic decompensation.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034